Trials / Terminated
TerminatedNCT00562887
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
A Phase 2B, Multi-Center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects With Moderately to Severely Active Crohn's Disease.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 246 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo | every 4 weeks, IV |
| BIOLOGICAL | ABT-874 | 400 mg IV every 4 weeks |
| BIOLOGICAL | ABT-874 | 700 mg IV every 4 weeks |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2010-04-01
- First posted
- 2007-11-26
- Last updated
- 2011-08-23
Locations
61 sites across 7 countries: United States, Australia, Austria, Belgium, Canada, Denmark, Puerto Rico
Source: ClinicalTrials.gov record NCT00562887. Inclusion in this directory is not an endorsement.